Prevalence of Osteoporosis in Older Male Veterans Receiving Hip-containing Computed Tomography Scans: Opportunistic Use of Biomechanical Computed Tomography Analysis (BCT)
Overview
Affiliations
Purpose: Osteoporosis care in men is suboptimal due to low rates of DXA testing and treatment. Biomechanical computed tomography analysis (BCT) can be applied "opportunistically" to prior hip-containing CT scans to measure femoral bone strength and hip BMD.
Methods: In this retrospective, cross-sectional study, we used BCT in male veterans with existing CT scans to investigate the prevalence of osteoporosis, defined by hip BMD (T-score ≤ - 2.5) or fragile bone strength (≤ 3500 N). 577 men, age ≥ 65 with abdominal/pelvic CTs performed in 2017-2019, were randomly selected for BCT analysis. Clinical data were collected via electronic health records and used with the femoral neck BMD T-score from BCT to estimate 10-year hip fracture risks by FRAX.
Results: Prevalence of osteoporosis by BCT increased with age (13.5% age 65-74; 18.2% age 75-84; 34.3% age ≥ 85), with an estimated overall prevalence of 18.3% for men age ≥ 65. In those with osteoporosis (n = 108/577), only 38.0% (41/108) had a prior DXA and 18.6% (7/108) had received osteoporosis pharmacotherapy. Elevated hip fracture risk by FRAX (≥ 3%) did not fully capture those with fragile bone strength. In a multivariate logistic regression model adjusted for age, BMI, race, and CT location, end stage renal disease (odds ratio 7.4; 95% confidence interval 2.3-23.9), COPD (2.2; 1.2-4.0), and high-dose inhaled corticosteroid use (3.7; 1.2-11.8) were associated with increased odds of having osteoporosis by BCT.
Conclusion: Opportunistic BCT in male veterans provides an additional avenue to identify patients who are at high risk of fractures.
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes.
Ruggiero C, Caffarelli C, Calsolaro V, Tafaro L, Riuzzi F, Bubba V Drugs Aging. 2025; 42(1):21-38.
PMID: 39775765 DOI: 10.1007/s40266-024-01163-4.
Lin J, Hearn C, Getzen E, Long Q, Lee D, Keaveny T Eur Urol Oncol. 2023; 7(4):794-803.
PMID: 37926618 PMC: 11268319. DOI: 10.1016/j.euo.2023.10.016.